RxDoctor Payments Data

John Knight, MD

Internal Medicine · Huntsville, TXNPI 1013080761

Payments from drug & device makers

$219in general payments, 2019–2025

Across 11 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$67
  • Medtronic$60
  • Abbott$22
  • Lilly USA, LLC$17
  • Novo Nordisk$14
  • Genentech USA, Inc.$14
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$219 in reported general payments places this provider in the 45th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$22,549
Medicare patients
85
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$118,206
MounjaroTirzepatide43$52,242
JardianceEmpagliflozin57$44,591
EliquisApixaban67$37,459
TrulicityDulaglutide18$20,726
JanuviaSitagliptin Phosphate26$18,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,230
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$3,190
Wixela InhubFluticasone Propion/Salmeterol22$2,900
FarxigaDapagliflozin Propanediol25$2,649
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen142$2,308
Levothyroxine Sodium195$2,263
Atorvastatin Calcium273$2,201
Lisinopril181$1,883
Metoprolol Succinate91$1,693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$118,206104 claims
Lilly USA, LLCMounjaro, Trulicity$17$72,96861 claims
PfizerEliquis$67$37,45967 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Huntsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →